Background The goal of chronic hepatitis C treatment is to remove the virus to avoid
progression of HCV-related disease. Sustained virologic response (SVR) is the most widely …

Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense
research and development efforts, a large number of direct-acting antiviral drugs are now …

BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis
in chronic liver disease; however, it is invasive, with the potential for serious complications …

Most direct‐acting antivirals (DAAs) that are being developed as therapy against hepatitis C
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …

New treatments for hepatitis C virus (HCV) may be highly effective but are associated with
substantial costs that may compel clinicians and patients to consider delaying treatment …

Background & Aims Direct-acting antivirals (DAAs) are effective in treatment of hepatitis C
virus (HCV) genotype 1 infection, but their cost and value have been debated. We performed …

Background: Prevalence of chronic hepatitis C virus (HCV) infection is high among
incarcerated persons in the United States. New, short-duration, high-efficacy therapies may …

Background New direct-acting antivirals (DAAs) are highly effective for hepatitis C virus
(HCV) treatment. However, their prices have been widely debated. Decision-analytic models …

Two selective inhibitors of the hepatitis C virus (HCV) protease nearly double the cure rates
for this infection when combined with peginterferon alfa and ribavirin. These drugs …

Background Individualized medicine (IM) is a rapidly evolving field that is associated with
both visions of more effective care at lower costs and fears of highly priced, low-value …